Artiva Biotherapeutics Inc ARTV

US Biotechnology

$4.07 ▼ -3.55% ($-0.15)

⬇️ Below Yest. Low 🔥 High Short Interest 🎢 High Beta 📅 Earnings This Week

Open $4.17

Prev Close $4.22

Day Range $4.04 – $4.23

52W Range $2.96 – $14.53

Market Cap $206.32M

Beta 5.22

EPS (TTM) $-3.43

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-07-19
Shares Out.	48,890,000
Website	artivabio.com/ ↗
Phone	18582674467
Employees	115
Revenue	$0
Gross Profit	$0
Net Income	-$25.0M
Free Cash Flow	-$76.9M
Total Assets	$368.6M
Total Liabilities	$21.1M
Equity	$347.5M

About Artiva Biotherapeutics Inc

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Artiva Biotherapeutics Inc is a publicly traded company under the ticker symbol ARTV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.